Healthcare Services

A key trend shaping the Next-Generation Antibody Therapeutics Market involves the Revolutionizing Antibody Therapeutics By Exploring Cutting-Edge Technologies And Breakthroughs In Next-Generation Solutions

April 3, 2026April 3, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Market Size Of The Next-Generation Antibody Therapeutics Market In 2026 And What Value Is Projected For 2030?

The next-generation antibody therapeutics market size has experienced swift expansion in recent years. It is anticipated to grow from $7.56 billion in 2025 to $8.35 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.4%. The market’s growth during the past period can be linked to an increase in monoclonal antibody approvals, the rising occurrence of cancer, the broadening of biologics manufacturing capacity, higher investment in pharmaceutical R&D, and refined regulatory pathways for biologics.

The next-generation antibody therapeutics market size is projected to experience swift expansion over the coming years. This market is anticipated to reach $12.63 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.9%. Factors contributing to this growth during the projection period include progress in antibody engineering technologies, an escalating need for targeted treatments, the growing occurrence of chronic and autoimmune conditions, the broadening of clinical trials in developing regions, and increasing collaborations between biotechnology and pharmaceutical firms. Key developments foreseen in this period encompass the broadening of bispecific and multispecific antibody platforms, a rising uptake of antibody-drug conjugates in cancer treatment, heightened attention on antibodies with high affinity and extended action, an expanding clinical pipeline for rare and orphan diseases, and a move towards personalized antibody-based therapeutic approaches.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12678&type=smp

Which Growth Drivers Are Contributing To The Progress Of The Next-Generation Antibody Therapeutics Market?

The rising occurrence of chronic ailments is anticipated to drive expansion in the next-generation antibody therapeutics market in the future. These enduring health conditions persist for a year or more, requiring ongoing medical attention, limiting daily routines, or a combination of both factors. For individuals grappling with chronic illnesses, next-generation antibody therapeutics offer a therapeutic role by providing more targeted treatment, thereby improving patient outcomes. For example, data from January 2023, published by the National Center for Biotechnology Information (NCBI), a US-based National Library of Medicine, indicated a forecast that by 2050, the population of individuals aged 50 years and older living with at least one chronic illness is set to increase by 99.5%, reaching 142.66 million. Consequently, the expanding prevalence of chronic diseases is fueling the growth of the next-generation antibody therapeutics market.

What Are The Key Segments Of The Next-Generation Antibody Therapeutics Market?

The next-generation antibody therapeutics market covered in this report is segmented –

1) By Types Of Antibodies: Monoclonal Antibodies, Polyclonal Antibodies, Bispecific Antibodies, Antibody-Drug Conjugates, Other Types

2) By Therapeutic Area: Oncology, Autoimmune Diseases, Infectious Diseases, Neurodegenerative Disorders, Other Therapeutic Areas

3) By End-User: Hospitals And Clinics, Research Institutes, Pharmaceutical And Biotechnology Companies, Other End-Users

Subsegments:

1) By Monoclonal Antibodies: IgG Monoclonal Antibodies, IgM Monoclonal Antibodies

2) By Polyclonal Antibodies: Serum-Derived Polyclonal Antibodies, Hybridoma-Derived Polyclonal Antibodies

3) By Bispecific Antibodies: Dual-Targeting Antibodies, Single-Chain Variable Fragment (scFv) Antibodies

4) By Antibody-Drug Conjugates (ADCs): Targeted ADCs, Payload Types

5) By Other Types: Nanobodies, Engineered Antibodies

Which Trends Are Shaping The Future Of The Next-Generation Antibody Therapeutics Market?

Leading companies within the next-generation antibody therapeutics market are prioritizing the development of technological breakthroughs, exemplified by their proprietary Molecular Indexing of Proteins by Self-Assembly (MIPSA) technology. The goal is to improve protein identification and characterization, ultimately leading to more precise and impactful treatments. These advancements are designed to enhance therapeutic profiles, decrease expenditures, and tackle intricate diseases with superior accuracy. Molecular Indexing of Proteins by Self-Assembly (MIPSA) functions by arranging protein molecules into structured assemblies, which allows for more effective analysis and quantification. This approach significantly boosts the sensitivity and accuracy of protein detection, making it highly beneficial for research and diagnostic purposes. For example, in January 2024, Infinity Bio, Inc., a US-based biotechnology company, unveiled a new antibody profiling platform. This platform leverages MIPSA technology for efficient and cost-effective analysis of immune responses, intending to foster a deeper understanding of diseases and enable more personalized treatment strategies.

Who Are The Leading Companies Operating In The Next-Generation Antibody Therapeutics Market?

Major companies operating in the next-generation antibody therapeutics market are Pfizer Inc., F. Hoffmann‑La Roche Ltd., Bristol‑Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Amgen Inc., Regeneron Pharmaceuticals Inc., Biogen Inc., Genentech Inc., Kyowa Hakko Kirin Co. Ltd., Seagen Inc., Seattle Genetics Inc., Xencor Inc., ImmunoGen Inc., Genmab A/S, Zymeworks Inc., NBE‑Therapeutics AG, Daiichi Sankyo Company Limited, Merck & Co Inc., Novartis AG, AbCellera Biologics Inc., Sotio Biotech, F‑Star Therapeutics Ltd., ADC Therapeutics SA, Harbour BioMed

Read the full next-generation antibody therapeutics market report here:

https://www.thebusinessresearchcompany.com/report/next-generation-antibody-therapeutics-global-market-report

What Are The Leading Geographic Regions In The Next-Generation Antibody Therapeutics Market?

North America was the largest region in the next-generation antibody therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next-generation antibody therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Next-Generation Antibody Therapeutics Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12678&type=smp

Browse Through More Reports Similar to the Global Next-Generation Antibody Therapeutics Market 2026, By The Business Research Company

Next Generation Sequencing Global Market Report

https://www.thebusinessresearchcompany.com/report/next-generation-sequencing-global-market-report

Next Generation Military Power Supply Global Market Report

https://www.thebusinessresearchcompany.com/report/next-generation-military-power-supply-global-market-report

Next Generation Computing Global Market Report

https://www.thebusinessresearchcompany.com/report/next-generation-computing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795